The Food and Drug Administration (FDA) recently approved dual CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib in combination with other agents for the treatment of hormone receptor positive (HR+) advanced or metastatic breast cancer (A/MBC), as well as other subtypes of breast cancer. Here, NR4A1 is linked to breast cancer.